Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLE/PIB 8-Week Treatment in Acute HCV
NCT04903626Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2021
- Primary completion
- Sep 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 3 trial of glecaprevir, pibrentasvir in hepatitis C virus infection, sponsored by AbbVie Inc.. Started Aug 2021; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT04903626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903626.